LBA Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

LBA Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$18K	Buy	553 +200	+57%	+$6.83K	0.01%	280
2016 Q4	$13K	Buy	353 +100	+40%	+$3.99K	0.01%	304
2016 Q3	$12K	Sell	253 -34	-12%	-$1.77K	0.01%	312
2016 Q2	$14K	Buy	287 +34	+13%	+$1.81K	0.01%	285
2016 Q1	$14K	Buy	253 +103	+69%	+$6.04K	0.01%	277
2015 Q4	$10K	Hold	150	–	–	0.01%	296
2015 Q3	$8K	Hold	150	–	–	0.01%	267
2015 Q2	$9K	Hold	150	–	–	0.01%	249
2015 Q1	$9K	Hold	150	–	–	0.01%	242
2014 Q4	$9K	Hold	150	–	–	0.01%	233
2014 Q3	$8K	Hold	150	–	–	0.01%	295
2014 Q2	$8K	Buy	+150	New	+$7.67K	0.01%	216

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

LBA Wealth Management's TEVA Position: Q1 2017 in Review

LBA Wealth Management increased its Teva Pharmaceuticals (TEVA) stake by 57% in Q1 2017, buying an estimated $6.83K and bringing the position to 553 shares worth $18K. The position accounts for 0.01% of the portfolio, ranked #280.

LBA Wealth Management first reported a position in TEVA in Q2 2014 and has held it in 12 quarters since. 686 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

LBA Wealth Management held 553 shares of Teva Pharmaceuticals worth $18K as of Q1 2017.
LBA Wealth Management bought 200 Teva Pharmaceuticals shares in Q1 2017, an estimated $6.83K.
Teva Pharmaceuticals made up 0.01% of LBA Wealth Management's portfolio in Q1 2017, its #280 holding.
LBA Wealth Management first reported a position in Teva Pharmaceuticals in Q2 2014 and has held it in 12 quarters since.
686 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2017.

Based on LBA Wealth Management's 13F filing for Q1 2017, filed 9 May 2017.